Dermatologicals in Uruguay

October 2024 | | ID: D7C4A8A1405EN
Euromonitor International Ltd

Abstracts

Due to climate change, Uruguay is experiencing warmer weather and an extended rainfall season during 2024. These weather conditions have resulted in a strong outbreak of the mosquito-spread virus, dengue fever, which will give extra strength to the category. As a result, antipruritics is becoming the best performing dermatological in 2024, which is led by Urufarma with Prurisedan, followed by Spefar with Cortifar. The category remains very active in terms of product innovation. For example, Spef...

Euromonitor International's Dermatologicals in Uruguay report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2019-2023, allowing you to identify the sectors driving growth. Forecasts to 2028 illustrate how the market is set to change.

Product coverage: Antiparasitics/Lice (Head and Body) Treatments, Antipruritics, Cold Sore Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Dermatologicals, Topical Allergy Remedies/Antihistamines, Topical Antifungals, Topical Germicidals/Antiseptics, Vaginal Antifungals.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Dermatologicals market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

Dermatologicals in Uruguay
Euromonitor International
October 2024

LIST OF CONTENTS AND TABLES

DERMATOLOGICALS IN URUGUAY
KEY DATA FINDINGS

2024 DEVELOPMENTS

Dengue outbreak supports sales of antipruritics in 2024
Dermatologicals sales benefit as buying from Argentina declines
Mega Labs and Bayer account for almost half of all dermatological sales
PROSPECTS AND OPPORTUNITIES
Outdoor activity positively impacts sales of antifungal products in 2024
Innovation, advertising and promotional investments drive growth
E-commerce and omnichannel approaches have a distinct advantage
CATEGORY DATA
Table 1 Sales of Dermatologicals by Category: Value 2019-2024
Table 2 Sales of Dermatologicals by Category: % Value Growth 2019-2024
Table 3 NBO Company Shares of Dermatologicals: % Value 2020-2024
Table 4 LBN Brand Shares of Dermatologicals: % Value 2021-2024
Table 5 Forecast Sales of Dermatologicals by Category: Value 2024-2029
Table 6 Forecast Sales of Dermatologicals by Category: % Value Growth 2024-2029
CONSUMER HEALTH IN URUGUAY
EXECUTIVE SUMMARY
Consumer health in 2024: The big picture

2024 KEY TRENDS

Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2019-2024
Table 8 Life Expectancy at Birth 2019-2024
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2019-2024
Table 10 Sales of Consumer Health by Category: % Value Growth 2019-2024
Table 11 NBO Company Shares of Consumer Health: % Value 2020-2024
Table 12 LBN Brand Shares of Consumer Health: % Value 2021-2024
Table 13 Penetration of Private Label by Category: % Value 2019-2024
Table 14 Distribution of Consumer Health by Format: % Value 2019-2024
Table 15 Distribution of Consumer Health by Format and Category: % Value 2024
Table 16 Forecast Sales of Consumer Health by Category: Value 2024-2029
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2024-2029
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
DISCLAIMER
DEFINITIONS
SOURCES
Summary 1 Research Sources